Maplirpacept

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

LymphomaMultiple MyelomaDiffuse Large B-Cell Lymphoma

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

1

Zofran

Novartis

Preclinical

22

Cabenuva

GSK

Preclinical

13

Norvir

AbbVie

Preclinical

14

Maplirpacept

Pfizer

Phase 2

15

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

16

Kenalog

BBausch Health Americas, Inc.

Preclinical

17

Nuvigil

NNuvo Research GmbH

Preclinical

18

Systemic Therapy

Bristol-Myers Squibb

Preclinical

19

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—10

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—Show 30 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Multiple Myeloma3 trials

A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

Terminated·Pfizer·Phase 1·NCT03530683·189 enrolled

A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China

Completed·Pfizer·Phase 1·NCT05896774·10 enrolled

A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE AND ELRANATAMAB IN COMBINATION WITH PF-07901801 IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA

Active, not recruiting·Pfizer·Phase 1·NCT05675449·59 enrolled

Diffuse Large B-Cell Lymphoma2 trials

Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Terminated·Pfizer·Phase 1/2·NCT05626322·6 enrolled

TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Active, not recruiting·MMayo Clinic·Phase 2·NCT05507541·10 enrolled

Ovarian Cancer1 trial

Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer

Terminated·Pfizer·Phase 1/2·NCT05261490·10 enrolled

Lymphoma1 trial

A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.

Active, not recruiting·Pfizer·Phase 1/2·NCT05896163·24 enrolled

Hematologic Malignancies1 trial

A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies

Completed·Pfizer·Phase 1·NCT05567887·7 enrolled

Details

Drug Info

Related News